Strongbridge Biopharma | search
Click here to view Strongbridge Biopharma news from 60+ newspapers.
Bookmark or Share- Strongbridge Biopharma plc Announces Shareholder Approval - GlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “ Company ” or “ Strongbridge ”) today announced that its shareholders have...
- Overview | Xeris Biopharma Holdings, Inc.Prior to joining Xeris, Mr. Conner served as Chief Compliance Officer at Strongbridge Biopharma prior to being acquired by Xeris in the Fall of 2021. Prior to these positions, Mr. Conner served as the Assistant Compliance Officer for the U.S and Canada at Shire Pharmaceuticals.
- Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris ...Strongbridge’s rare endocrine franchise includes RECORLEV ® (levoketoconazole), an adrenal steroidogenesis inhibitor with a New Drug Application that is currently under review by the FDA for...
- Xeris Pharmaceuticals to acquire Strongbridge Biopharma for $267mXeris Pharmaceuticals has signed a definitive agreement to acquire Strongbridge Biopharma for stock and contingent value rights (CVRs) estimated at around $267m.
- Xeris Pharmaceuticals Completes Acquisition of Strongbridge BiopharmaUnder the terms of the acquisition agreement, the businesses of Xeris and Strongbridge are now combined under Xeris Biopharma Holdings, Inc. (“Xeris Biopharma Holdings”). Strongbridge shares and Xeris shares ceased trading on the Nasdaq Global Select Market (“Nasdaq”) at the close of business today.
More
